

## **Prevalence of Bacteriologically-Confirmed Tuberculosis in Urban Blantyre, Malawi 2019-20: Substantial Decline Compared to 2013-14 National Survey**

### **Short title: Reduced Tuberculosis Prevalence in Blantyre, Malawi**

Helena R A Feasey<sup>1,2</sup>, McEwen Khundi<sup>1,2</sup>, Rebecca Nzawa Soko<sup>1</sup>, Emily Nightingale<sup>2</sup>, Rachael M Burke<sup>1,2</sup>, Marc Y R Henrion<sup>1,5</sup>, Mphatso D Phiri<sup>1,5</sup>, Helen E Burchett<sup>2</sup>, Lingstone Chiume<sup>1</sup>, Marriott Nliwasa<sup>1,3</sup>, Hussein H Twabi<sup>1,3</sup>, James A Mpunga<sup>4</sup>, Peter MacPherson<sup>1,2,6</sup>, Elizabeth L Corbett<sup>2</sup>

<sup>1</sup>Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi, <sup>2</sup>London School of Hygiene and Tropical Medicine, UK, <sup>3</sup>Helse Nord Tuberculosis Initiative, Kamuzu University of Health Sciences, Malawi, <sup>4</sup>National Tuberculosis Control Programme, Malawi, <sup>5</sup>Liverpool School of Tropical Medicine, UK, <sup>6</sup>School of Health & Wellbeing, University of Glasgow, UK

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

1 **Abstract (299 words)**

2 Recent evidence shows rapidly changing tuberculosis (TB) epidemiology in Southern and  
3 Eastern Africa, with need for subdistrict prevalence estimates to guide targeted  
4 interventions. We conducted a TB prevalence survey to estimate current TB burden in  
5 Blantyre city, Malawi. From May 2019 to March 2020, 215 households in middle/high-  
6 density residential Blantyre, were randomly-selected from each of 72 clusters. Consenting  
7 eligible participants (household residents  $\geq 18$  years) were interviewed, including for cough  
8 (any duration), and offered HIV testing and chest X-ray; participants with cough and/or  
9 abnormal X-ray provided two sputum samples for microscopy, Xpert MTB/Rif and  
10 mycobacterial culture. TB disease prevalence and risk factors for prevalent TB were  
11 calculated using complete case analysis, multiple imputation, and inverse probability  
12 weighting. Of 20,899 eligible adults, 15,897 (76%) were interviewed, 13,490/15,897 (85%)  
13 had X-ray, and 1,120/1,395 (80%) sputum-eligible participants produced at least one  
14 specimen, giving 15,318 complete cases (5,895, 38% men). 29/15,318 had bacteriologically-  
15 confirmed TB (189 per 100,000 complete case (cc) / 150 per 100,000 with inverse weighting  
16 (iw) ). Men had higher burden (cc: 305 [95% CI:144-645] per 100,000) than women (cc: 117  
17 [95% CI:65-211] per 100,000): cc adjusted odds ratio (aOR) 2.70 (1.26-5.78). Other  
18 significant risk factors for prevalent TB on complete case analysis were working age (25-49  
19 years) and previous TB treatment, but not HIV status. Multivariable analysis of imputed data  
20 was limited by small numbers, but previous TB and age group 25-49 years remained  
21 significantly associated with higher TB prevalence.  
22  
23 TB prevalence for Blantyre was considerably lower than the 1,014 per 100,000 for urban  
24 Malawi in the 2013-14 national survey, at 150-189 per 100,000 adults, but some groups,

25 notably men, remain disproportionately affected. TB case-finding is still needed for TB  
26 elimination in Blantyre, and similar urban centres, but should focus on reaching the highest  
27 risk groups, such as older men.  
28

## 29 Introduction

30 The high tuberculosis (TB) incidence in Southern and Eastern African countries has been  
31 driven by generalised HIV epidemics [1], together with poverty and urbanisation. In the  
32 WHO African Region, TB incidence declined by 22% between 2015 and 2021 [2], concurrent  
33 with continuing decreases in HIV incidence and HIV-related deaths [3, 4]. In Malawi,  
34 estimated TB incidence has declined from 338 per 100,000 in 2010 to 132 per 100,000 in  
35 2021 [2]. The most recent national TB prevalence survey conducted in 2013-14 estimated an  
36 urban prevalence of bacteriologically-confirmed pulmonary TB of 1,014 per 100,000 adults  
37 (15+ years) [5, 6] (including Blantyre, the second largest city in Malawi), prompting  
38 government and donor investment in TB case-finding activities focused on urban areas. In  
39 this time of rapidly declining estimated TB incidence, understanding true TB burden can  
40 support more effective National TB Programme (NTP) interventions as countries work  
41 towards TB elimination goals [7]. As epidemics decline, TB is likely to become more  
42 concentrated in marginalised and harder-to-reach groups, requiring increasingly targeted  
43 case-finding strategies [8, 9].

44

45 TB case-notification rates (CNRs) have been declining in Blantyre [10], likely reflecting the  
46 combined effects of increasing coverage with antiretroviral therapy (ART) [11, 12] and use  
47 of TB preventive therapy for people living with HIV (PLHIV), as well as TB case-finding and  
48 prevention activities. HIV testing and treatment services have been successfully scaled-up to  
49 reach UNAIDS 90-90-90 targets for 2020 in Malawi [12, 13]. However, case-notifications are  
50 an imperfect guide to TB burden in a population, since they do not include people with TB  
51 who remain undiagnosed or may not reach care [2]. As such, low TB CNRs can reflect either

52 under-notification or low incidence of TB. While TB prevalence surveys are laborious and  
53 expensive they likely provide the least biased approach to estimating disease burden [14].

54

55 The Sustainable Community-based Active case-finding for Lung hEalth (SCALE) trial was  
56 designed to investigate the impact of door-to-door active case-finding (ACF) on TB case-  
57 notification rates and, if sufficiently powered, the prevalence of undiagnosed TB [15] in  
58 Blantyre. In 2019-2020, a TB prevalence survey was, therefore, conducted in all SCALE  
59 clusters before the ACF intervention to determine the baseline prevalence of undiagnosed  
60 TB and re-evaluate power for intended trial outcomes. The aim was to estimate the burden  
61 of TB amongst adults 18 years or older in middle-to-high density urban Blantyre, Malawi.

## 62 **Methods**

63 We undertook a cluster-based, cross-sectional TB prevalence survey in middle- to high-  
64 density residential areas of Blantyre, Malawi between May 2019 and March 2020. Blantyre  
65 City is located in the Southern Region of Malawi, and has a population of approximately  
66 800,250 [16] mostly living in several informal urban settlements built on underserved land  
67 [17]. Although health care is free at the point of care, poorly developed road networks limit  
68 access to health and other municipal services. These informal settlements were the focus of  
69 this study, which excluded the smaller, central, and more affluent residential and industrial  
70 areas. Informal residential areas were demarcated into 72 clusters of approximately 4,400  
71 adult residents each using Community Health Worker catchment area boundaries and  
72 population estimates from a city-wide enumeration census conducted with Blantyre District  
73 Health Office (DHO) in 2015. The study covered approximately 75% of the geographical area  
74 of Blantyre City.

75

76 In each cluster, 115 households were randomly selected from a sampling frame of all  
77 household GPS co-ordinates obtained from Google Earth, aiming to recruit 215 adults (aged  
78 18 and above) per cluster. Each household was visited at least three times to maximise  
79 recruitment of all adult household members, with an initial visit to sensitise household  
80 members and book survey appointments. Survey teams covered two clusters per week, with  
81 initial activities taking four to five days per cluster, followed by repeat visits to include  
82 previously unavailable residents in March 2020.

83

84 Household residents were defined as those who usually ate and slept in the same residence.

85 All adult (18 years and over) household residents were eligible for participation if willing and

86 able to provide written or witnessed informed consent. A household questionnaire was  
87 conducted with one consenting adult household member (the household head if present) to  
88 capture household-level variables including socioeconomic indicators and the age and sex of  
89 all household residents. Individual questionnaires were then conducted with all consenting  
90 household members, including socio-demographics, a symptom screen for cough of any  
91 duration, and brief details of previous HIV and TB testing and care. Participants reporting  
92 cough were given two sputum pots, with one collected immediately for microscopy and  
93 culture, if possible, and the second collected for Xpert MTB/Rif after an hour or more. All  
94 participants were asked to attend a temporary tented digital chest X-ray and HIV testing  
95 camp located within each cluster during recruitment days.

96  
97 Chest X-ray used Min X-ray Commander CMDR-2S-T, with films classed as normal or having  
98 any abnormality by a trained radiographer, with reference to results of Qure.ai (version 2)  
99 computer-aided detection software. All participants with abnormal X-rays were requested  
100 to provide two spot sputum samples. The first sample was taken immediately and the  
101 second an hour later. HIV testing used OraQuick (OraSure) and Determine (Alere) finger-  
102 prick tests in parallel, with confirmation by Uni-Gold (Trinity Biotech) for positive results,  
103 was offered to all participants not on ART. Participants on ART were offered Uni-Gold  
104 (Trinity Biotech) confirmatory testing only.

105  
106 All participants with abnormal X-rays (any abnormality) were referred to an X-ray clinic for  
107 review by clinician in a tented community clinic the following week. Those identified as HIV  
108 positive and not on ART through the onsite HIV testing were given onsite counselling and  
109 referred to the local government HIV clinic for ART initiation.

110

## 111 **Laboratory methods**

112 Sputum samples were processed in the Malawi-Liverpool-Wellcome (MLW)/Kamuzu  
113 University of Health Sciences (KUHeS) TB Laboratory, with the first specimen used for  
114 fluorescent microscopy (auramine) and liquid culture (Bactec MGIT 960, Becton Dickinson,  
115 Franklin Lakes, NJ, USA) and the second specimen used for microscopy and Xpert MTB/Rif  
116 (Cepheid, Sunnyvale, CA, USA). Mycobacterial Growth Indicator Tube (MGIT) positive  
117 samples were confirmed by Ziehl-Neelsen microscopy (morphology/cording) and MPT64 (SD  
118 Bioline, Yongin, Republic of Korea) antigen testing to identify *Mycobacterium tuberculosis*  
119 (MTB). Those negative on MPT64 were further incubated at different temperatures on  
120 Löwenstein-Jensen (LJ) slopes and classified as non-tuberculous mycobacteria or MTB based  
121 on subsequent morphology and growth characteristics.

122

123 Participants with positive microscopy, Xpert or MTB culture results were classified as having  
124 bacteriologically-confirmed TB. For this survey, an Xpert MTB/Rif G4 trace result was  
125 considered positive for MTB. Smear-positive TB participants were defined as those with a  
126 direct smear indicating acid fast bacilli. Confirmed TB participants were actively traced for  
127 assisted registration for TB treatment at local government clinics.

128

## 129 **Statistical methods**

130 The calculated sample size of 14,511 participants was based on the ability to estimate an  
131 overall TB prevalence of 900 per 100,000 with absolute precision of +/- 250,000 per 100,000  
132 (relative precision 27.8%) and a design effect to account for clustering of 2.25. Based on  
133 previous work by NTP and our research group in Blantyre, a relatively high non-participation



134 rate of 25% was also assumed. This final sample was rounded up to 15,500 adults (215 per  
135 cluster).

136

137 Data was summarised by frequencies, percentages, and medians as appropriate, with chi-  
138 squared tests to examine differences between groups, such as participation rate by sex.

139

140 Following WHO-recommended best-practice analytical methods [18, 19], we estimated TB  
141 prevalence using logistic regression models with robust standard errors (calculated from  
142 observed between-cluster variability) to account for clustering using three approaches to  
143 missing data: 1) complete case analysis (excluding participants eligible for sputum  
144 submission but for whom smear, Xpert MTB/Rif and/or culture data were missing); 2)  
145 multiple imputation of missing values for sex, age, HIV status, symptom status, X-ray status,  
146 sputum results, previous TB, TB contact, crowding and wealth variables, and 3) imputation  
147 of missing data for those eligible for sputum submission (cough or abnormal X-ray) with  
148 inverse probability weighting to represent all eligible individuals. For multiple imputation of  
149 missing values, the predictive mean matching imputation model included all the variables  
150 investigated as predictors of bacteriologically-confirmed and smear-positive TB in the  
151 multivariable regression model, twenty-five imputed datasets were created, and estimates  
152 were combined using Rubin's rules [20]. Sensitivity analysis was also conducted for an  
153 alternate definition of a complete case, restricted to participants with available sputum  
154 result data and those who completed both screens.

155

156 All analyses were done with R version 4.2.1, using packages including mice [21], lme4 [22]  
157 and sandwich [23]. This prevalence survey was part of the SCALE trial with registration  
158 number ISRCTN11400592.

159

#### 160 *Data and reproducibility*

161 Data and code to reproduce this analysis is available from <https://osf.io/eu2xf/>.

162

#### 163 *Ethics*

164 The survey protocol was approved by the ethics committee of the London School of Hygiene  
165 and Tropical Medicine and Kamuzu University of Health Sciences in Malawi. Written (or  
166 witnessed thumbprint if illiterate) informed consent was obtained from all participants.

167

168 **Results**

169 Between May 2019 and March 2020, 20,899 eligible adults were enumerated in 7,175  
170 randomly selected and visited households, although many were not physically present  
171 during the household visit. 76% (15,897) participated in the survey and underwent symptom  
172 screen; 13,490 (85%) had chest X-ray. 1,394/15,897 (9%) participants were eligible to submit  
173 sputum through reporting a cough of any duration and/or abnormal X-ray. Of these, 1,140  
174 (82%) submitted at least one sputum sample and 900 submitted two sputum samples  
175 (Figure 1).

176

177 **Figure 1: Schematic diagram of number of participants screened for TB & HIV**

178

179 Participation rates varied substantially by sex and age group. Participation was higher in  
180 women (9,766 of 11,283 [86.6]) than men (6,131 of 9,616 [63.8%],  $\chi^2$   $p < 0.001$ ). The  
181 participation rate was highest in people aged 18-24 years (5997 of 7149 [83.9%]) and lower  
182 in those aged 25-49 years (8,006 of 10,881 [73.6%]) and 50+ years (1,885 of 2,476 [76.1%],  
183  $\chi^2$   $p < 0.0001$ ). The difference in age participation was driven by men, with the lowest  
184 participation rates in working-age men (2,738/4,854 [56.4%] men aged 25-49).

185

186 HIV results were available for 11,709 participants of whom 179 (1.8%) were newly identified  
187 as HIV-positive, whilst 1,453 (11.9%) were confirmed as previously-known HIV-positive.

188 Overall, 1,971/15,897 (12.4%) participants were identified as HIV-positive, of whom  
189 1,741/1,971 (88.3%) were taking ART.

190

191 Previous TB was reported by 456 of 15,897 (2.9%) participants, with 24 (24/15897 [0.2%])  
 192 currently on TB treatment; 721 (4.5%) reported knowing someone who had received TB  
 193 treatment in the last 12-months.

194  
 195 Of the 1,395 participants eligible to submit sputum 1,120 had valid smear results, 1,075  
 196 valid culture results, and 900 valid Xpert MTB/Rif results. 579 sputum-eligible participants  
 197 were missing valid results from at least one sputum tests giving 15,318 complete cases  
 198 (Table 1). 29 participants were identified with bacteriologically-confirmed TB (one of whom  
 199 was already on TB treatment). Of those 29, nine were smear-positive (all confirmed by  
 200 Xpert MTB/Rif or culture) and the others Xpert/culture positive and smear negative (Figure  
 201 1 & Supplementary Table 1).

202

203 **Table 1: Prevalence of TB disease per 100,000 adults, with robust standard errors used to**  
 204 **calculate 95% confidence intervals**

	Total (n)	TB (n)	Prevalence (95% CI)		
			Complete case	Fully imputed	Inverse weighting
<i>All participants</i>	15318	29	189 (132-272)	139 (71-272)	150 (76-297)
<i>Sex</i>					
Female	9423	11	117 (65-211)	97 (54-176)	100 (55-183)
Male	5895	18	305 (144-645)	198 (94-415)	225 (105-479)
<i>Age</i>					
18-24	5811	5	86 (36-207)	82 (37-183)	65 (27-158)
25-49	4356	19	246 (92-657)	189 (77-468)	197 (73-531)
50+	582	5	281 (81-966)	277 (93-821)	283 (85-938)
<i>HIV status</i>					
HIV negative	15318	23	171 (114-257)	126 (84-189)	148 (97-228)
HIV positive	5895	6	320 (130-783)	270 (116-628)	292 (122-693)
<i>Previous diagnosis</i>					
No previous TB	14895	25	168 (113-248)	128 (87-189)	143 (96-214)
Previous TB	423	4	946 (329-2687)	613 (214-1742)	794 (270-2308)

205 Notes:

206 HIV status as identified through testing in prevalence survey, or if no test as reported in individual survey

207 5 of complete cases no age recorded (3 HIV negative, 1 HIV positive & 1 HIV unknown)

208 626 participants with HIV unknown status but no TB cases amongst them

209 Previous TB includes one currently on TB treatment

210 Of the 29 participants identified with bacteriologically-confirmed TB, 18 (62%) were male  
211 and the highest number were in the 25-49 age group (19 [66%]) (Table 1). In total 6/29  
212 (21%) with bacteriologically-confirmed TB were living with HIV, of whom five were taking  
213 ART and one was newly diagnosed. In addition, four (14%) of the 29 identified with  
214 prevalent TB reported a previous TB diagnosis (one currently on treatment) and two (7%)  
215 reported knowing someone who had started TB treatment in the last 12 months. Fourteen  
216 had a cough, of whom nine also had an abnormal chest X-ray. Twelve (41%, 95% CI: 24-61%)  
217 had an abnormal chest X-ray but no cough, and for three participants their cough result was  
218 missing (two had normal X-ray and one X-ray result was also missing). Overall, of the 29  
219 participants with prevalent bacteriologically-confirmed TB, ten (34%, 95% CI: 18-54%)  
220 reported no TB symptoms at household survey (cough, fever, night-sweats or weight-loss)  
221 (Supplementary Tables 1 & 2).

222

223 The overall prevalence of bacteriologically-confirmed TB was: 189 per 100,000 adults (95%  
224 CI 132-272) for the complete case model; 139 per 100,000 adults (95% CI: 71-272) for the  
225 multiple imputation model; and 150 per 100,000 adults (95% CI: 76-297) for the inverse  
226 probability weighted model (Figure 2). Sensitivity analysis with the alternate complete case  
227 definition gave a TB prevalence of 223 per 100,000 adults (95% CI: 155-320).

228

## 229 **Figure 2: Estimated tuberculosis prevalence by different analytical models**

230

231 TB prevalence varied considerably by sex, age, and HIV status. The inverse probability  
232 weighting model is considered to give the single best estimate of TB prevalence [19] and in  
233 our study we considered it most likely to be closest to the true prevalence since it adjusted

234 for the low participation rates amongst working age men (i.e. those aged 25-49 years). In  
235 this model male TB prevalence was more than twice as high as female prevalence (225 per  
236 100,000 [95% CI: 105-479] for males vs. 100 per 100,000 [95% 55-183] for females). TB  
237 prevalence was highest in the age group 50 years and over (283 per 100,000 [95% CI: 85-  
238 938]). TB prevalence was also higher in people living with HIV (PLHIV) at 292 per 100,000  
239 (95% CI: 122-693) compared to HIV-negative people (148 per 100,000 [95%CI: 97-228]).

240

241 The inverse probability weighting model gave a smear-positive TB prevalence of 37 per  
242 100,000 adults (95% CI: 9-169) (Supplementary Table 3). Smear-positive prevalence was  
243 higher for males (84 per 100,000 [95% CI: 18-400]) than females (18 per 100,000 [95%CI: 4-  
244 71]), higher amongst PLHIV (132 per 100,000 [95% CI: 33-520]) than those who are HIV  
245 negative (42 per 100,000 [95% CI: 20-88]), and highest in the age group 50 years and over  
246 (141 per 100,000 [95% CI: 23-852]). The overall highest smear-positive TB prevalence was  
247 amongst those who had previously been treated for TB at 349 per 100,000 (95% CI: 74-  
248 1640) compared to 42 per 100,000 (95% CI: 21-86) for those with no previous treatment.

249

250 On univariable analysis, male sex (OR 2.62, 95% CI: 1.17-6.14, compared to female), being  
251 aged 25-49 years (OR 2.86, 95% CI: 1.07-7.68 compared to 18-24 years) and previous TB (OR  
252 5.68, 95% CI: 1.96-16.42, compared to no previous TB treatment) were associated with  
253 increased odds of prevalent TB (Table 2). On multivariable analysis using the recommended  
254 inverse-weighting approach, only previous TB treatment (aOR 3.96, 95% CI: 1.16-13.49) and  
255 the age group 25-49 years (aOR 2.69, 95% CI: 1.00-7.26) remained significant predictors of  
256 prevalent TB (Table 2). Contact with someone with TB in the last 12 months, male sex, HIV  
257 status, crowding and wealth were not significantly associated with prevalent TB in the fully

258 adjusted model. However, this multivariable analysis was limited by the small numbers of  
 259 participants diagnosed with TB in each category. Due to the small numbers we present age  
 260 and HIV variables with only three and two categories respectively but analysis with full WHO  
 261 recommended age and HIV categories is presented in Supplementary Tables 4 and 5.

262

263 **Table 2: Risk factors for prevalent bacteriologically-confirmed TB, with robust standard**  
 264 **errors used to calculate 95% confidence intervals**

265

266

Variable	Univariate OR	Multivariate analysis		
		Complete case OR (95% CI)	Fully imputed OR (95% CI)	Inverse weighting OR (95% CI)
<i>Sex</i>				
Female	1	1	1	1
Male	2.62 (1.24-5.55)	2.70 (1.26-5.78)	2.03 (0.95-4.34)	2.04 (0.98-4.27)
<i>Age, years</i>				
18-24	1	1	1	1
25-49	2.86 (1.07-7.68)	2.97 (1.10-8.04)	2.33 (0.85-6.39)	2.69 (1.00-7.26)
50+	3.27 (0.95-11.32)	2.78 (0.78-9.87)	2.73 (0.87-8.59)	3.09 (0.92-10.42)
<i>HIV/ART status</i>				
HIV-	1	1	1	1
HIV+	1.87 (0.76-4.60)	1.28 (0.38-4.29)	1.70 (0.66-4.39)	1.42 (0.55-3.64)
<i>Previous TB</i>	5.68 (1.96-16.42)	3.95 (0.87-17.81)	3.29 (1.00-10.87)	3.96 (1.16-13.49)
<i>TB contact (within 12 months)</i>	1.59 (0.38-6.71)	1.38 (0.31-6.09)	1.31 (0.29-5.86)	1.29 (0.28-6.05)
<i>Crowding, persons per room</i>				
<1	1	1	1	1
1-2	1.50 (0.70-3.24)	1.67 (0.73-3.81)	1.69 (0.84-3.42)	1.96 (0.96-4.00)
>2	2.00 (0.44-9.04)	2.50 (0.45-13.86)	2.64 (0.50-13.82)	1.91 (0.37-9.73)
<i>Wealth quartile*</i>				
1	1	1	1	1
2	0.66 (0.21-2.08)	0.65 (0.20-2.11)	0.59 (0.18-1.97)	0.63 (0.17-2.31)
3	1.24 (0.47-3.26)	1.13 (0.40-3.19)	1.05 (0.37-2.96)	1.01 (0.36-2.86)
4 (top)	0.81 (0.28-2.32)	0.68 (0.20-2.28)	0.64 (0.20-2.08)	0.70 (0.22-2.21)

267

268 \* Probability of being below the poverty line from 1 (most likely) to 4 (least likely)

269

270 Significant predictors of prevalent smear-positive TB were male sex (OR 5.35 [95% CI: 1.02-  
 271 52.74]) and reported previous TB (OR 9.86, 95% CI: 1.00-52.01) on univariable analysis, but

272 no predictors were significant on multivariable analysis, likely due to the small numbers

273 involved (only nine smear-positive TB cases identified).

274



275 **Discussion**

276

277 The main finding from this survey is that the estimated adult prevalence of bacteriologically-  
278 confirmed pulmonary TB in Blantyre from this survey – 150 per 100,000 in the inverse  
279 probability weighted model – was more than 80% lower than the previous estimates for  
280 urban areas in the 2013-14 Malawi National TB Prevalence Survey (1,014 per 100,000 adults  
281 aged 15+) [5, 6]. This large decrease in TB prevalence over six years is likely due to both  
282 extensive local case-finding efforts and the concurrent rapid scale-up and high coverage of  
283 ART for treatment of HIV [12], and potentially TB preventive therapy for PLHIV. As expected  
284 [24], TB prevalence was higher amongst men, PLHIV, and those reporting previous TB, as  
285 well as among people aged 50 years and over. More than half of survey participants (52%)  
286 identified with TB through the survey did not self-report cough, and so would not have been  
287 identified through the symptom screen alone, highlighting the benefit of including X-ray or  
288 other screening strategies able to identify subclinical TB [25]. As TB epidemics decline in  
289 Southern and Eastern Africa, TB disease is likely to become increasingly concentrated in  
290 marginalised and hard-to-reach groups requiring adaptive targeted strategies informed by  
291 evidence such as local prevalence surveys.

292

293 Between the 2013-2014 NTP prevalence survey and this 2019-2020 survey, annual TB case  
294 notification rates, including bacteriologically confirmed TB, had been declining in Blantyre  
295 [10] with concurrent steep reductions in the percentage of primary care clinic attendees  
296 with bacteriologically-confirmed TB following self-presentation for investigation of TB  
297 symptoms. [26, 27]. As such, the pronounced decline in the prevalence of undiagnosed TB  
298 that we infer from comparing our results to the 2013-14 national survey is almost certainly  
299 correct, although our survey still demonstrates under-diagnosis of TB in Blantyre with a

300 prevalence to case-notification ratio of 4.49 (95% CI: 0.98–11.91) as reported elsewhere  
301 [10]. Undiagnosed infectious TB remains well above TB elimination targets, underscoring  
302 the need to continue appropriately targeted case-finding activities in Blantyre.

303

304 Our survey was intended to inform endpoints for a TB case-finding intervention trial, and so  
305 used random household sampling in purposively selected study-clusters, and 18+, not 15+,  
306 age to define adults as in the 2013-14 National survey. If anything, however, this is likely to  
307 over-estimate the municipal burden of undiagnosed TB in Blantyre City compared to  
308 National 2013-14 estimates. Our survey area covered most of urban Blantyre, from both  
309 geographic and population perspectives. Nationally, Blantyre City has the highest TB case-  
310 notifications, reflecting the more densely populated higher HIV-prevalence southern region  
311 of Malawi, making our finding even more striking as the 2013-14 urban estimates included  
312 cities with lower case-notifications [28, 29].

313

314 As expected from the literature [24] and recent national TB prevalence surveys [5, 6], TB  
315 prevalence was considerably higher amongst men than women, with the sex ratio increased  
316 from 1.33 (95% CI 0.94-1.87) in 2014 to 2.04 (95% CI 0.98-4.27) in this survey, highlighting  
317 the need for future case-finding efforts targeted at men. We had limited power to address  
318 HIV as a risk factor for undiagnosed TB, with only 6 of 29 (21%) people with prevalent TB  
319 being HIV positive, but this does suggest a decrease compared with an estimated 45% of  
320 patients diagnosed with TB being HIV-positive in the 2013-14 national TB prevalence survey  
321 [30]. This decrease is consistent with more complete diagnosis of HIV, better TB prevention  
322 (ART, isoniazid) and better implementation of sensitive (Xpert-based) screening guidelines  
323 for patients attending ART clinics in Malawi [7, 31]. It also reflects the estimated 20%

324 decline in HIV prevalence in Blantyre from 17.7% in 2015-16 to 14.2% in 2020-21 [32], and  
325 the concurrent improved management of HIV through ART, as evidenced by viral load  
326 suppression increasing from 59.5% in 2015-16 [3] to 81.0% in 2021 [32]. Although PLHIV  
327 have much higher incidence of TB disease, driving higher case-notifications at facilities, HIV  
328 has less impact on undiagnosed prevalent TB due to more rapid progression [33, 34]. In this  
329 survey in Blantyre, as in prevalence surveys across much of Africa [35, 36] most patients  
330 with undiagnosed infectious TB in the community were HIV-negative (23 out of 29 patients)  
331 As TB and HIV prevalence continues to fall, future community case-finding activities will  
332 need to be targeted at those at highest risk; for example in this prevalence survey, working  
333 age and older men who accounted for over half of all infectious TB patients, and tend to  
334 report suboptimal health-seeking [37] placing them at risk of remaining undiagnosed for  
335 prolonged periods without detection.

336

337 Previous TB treatment and older age groups were associated with higher undiagnosed TB  
338 prevalence, but other measured potential risk factors [38] (such as crowding and wealth)  
339 were not strongly associated with undiagnosed TB in this study. In part this may reflect our  
340 small number of cases. Nevertheless, the proportions of participants with infectious TB who  
341 had been previously treated (10% versus 14%) or were currently on TB treatment (3% vs 3%)  
342 were strikingly similar in 2019-20 and the 2013-14 National survey, and are consistent with  
343 a well-functioning routine treatment programme in Malawi. The age-group at greatest risk  
344 of TB (older adults) is also consistent with the 2013-14 National Survey findings, aligns with  
345 the known natural history of TB in endemic settings, and may also indicate the “aging” HIV  
346 epidemic in this global region [3, 32].

347

348 Half (15/29, 52%) of participants identified with TB in our Blantyre survey did not have a  
349 cough and would have been missed if only a cough symptom screen was used, and a third  
350 (10/29) had none of the WHO four TB symptoms. This aligns with other TB prevalence  
351 surveys [25] where typically half of those identified with TB were asymptomatic on the  
352 symptom screen. Again this has implications for future case-finding approaches, which  
353 should consider intensified screening with highly sensitive tools, such as digital chest X-ray,  
354 to identify people with subclinical TB in communities and clinics [39]. However, this may be  
355 less applicable in areas with higher TB prevalence since the pronounced declines in  
356 undiagnosed TB reported above were achieved in Blantyre with minimal systematic  
357 screening for sub-clinical TB.

358

359 This study has some limitations, including low precision from the small number of cases in  
360 our survey, due to lower than anticipated prevalence, and low rates of participation,  
361 particularly amongst working age men. Lower male participation has been seen in nearly all  
362 TB prevalence surveys [35], and future surveys should explore methods to increase  
363 participation such as further community engagement and study sites/times that are  
364 accessible to everyone, including working men, to reduce potential bias from under-  
365 participation and/or missing data. However, estimates from the use of different analytical  
366 models and imputation methods did not vary considerably suggesting bias due to missing  
367 data was limited. Two TB patients were diagnosed with TB but with records showing no  
368 cough and a normal X-ray, suggesting inaccurate data. Strengths of the survey include  
369 offering HIV testing, high rates of sputum submission from those eligible (82% overall and  
370 60% amongst those with no cough but abnormal chest X-ray) [40], linkage to care for those

371 diagnosed with TB and the use of all three sputum tests (smear microscopy, Xpert MTB/Rif  
372 and MGIT culture) to ensure high-sensitivity once sputum was submitted.

373

374 Our study demonstrates a substantial decrease in TB prevalence in urban Malawi over the  
375 eight years before the COVID-19 pandemic. To build on this and reverse any increase due to  
376 COVID-19 [41], future case-finding in Blantyre and similar urban centres in sub-Saharan  
377 Africa, should target the highest risk groups such as working-age and older men.

378

379

### 380 **Acknowledgments**

381 We acknowledge Vincent Phiri and George Sinjani for their help in setting up the data  
382 capture systems and overseeing fieldwork.

## 383 References

384

- 385 1. Surie D, Borgdorff MW, Cain KP, Click ES, DeCock KM, Yuen CM. Assessing the impact  
386 of antiretroviral therapy on tuberculosis notification rates among people with HIV: a  
387 descriptive analysis of 23 countries in sub-Saharan Africa, 2010-2015. *BMC Infect Dis.*  
388 2018;18(1):481.
- 389 2. World Health Organization. *Global Tuberculosis Report 2022*. 2022.
- 390 3. PHIA Project. *Malawi Population-based HIV Impact Assessment 2015-2016*. 2018.  
391 Columbia University; 2016.
- 392 4. Joshi K, Lessler J, Olawore O, Loevinsohn G, Bushey S, Tobian AAR, et al. Declining  
393 HIV incidence in sub-Saharan Africa: a systematic review and meta-analysis of empiric data.  
394 *J Int AIDS Soc.* 2021;24(10):e25818.
- 395 5. Ministry of Health National TB Control Programme. *Technical report: Malawi  
396 tuberculosis prevalence survey (2013–2014)*. 2016.
- 397 6. World Health Organization. *National Tuberculosis Prevalence Surveys 2007-2016*.  
398 2021.
- 399 7. Republic of Malawi Ministry of Health. *National Tuberculosis Control Programme -  
400 Programme Manual, Eighth Edition*. Malawi: Malawi Ministry of Health, Unit CHS; 2018.
- 401 8. European Centre for Disease Prevention and Control. *Guidance on tuberculosis  
402 control in vulnerable and hard-to-reach populations*. 2016.
- 403 9. Trauer JM, Dodd PJ, Gomes MGM, Gomez GB, Houben R, McBryde ES, et al. The  
404 Importance of Heterogeneity to the Epidemiology of Tuberculosis. *Clin Infect Dis.*  
405 2019;69(1):159-66.
- 406 10. Khundi M, Carpenter JR, Corbett EL, Feasey HRA, Soko RN, Nliwasa M, et al.  
407 Neighbourhood prevalence-to-notification ratios for adult bacteriologically-confirmed  
408 tuberculosis reveals hotspots of underdiagnosis in Blantyre, Malawi. *PLoS One.*  
409 2022;17(5):e0268749.
- 410 11. Burke RM, Henrion MYR, Mallewa J, Masamba L, Kalua T, Khundi M, et al. Incidence  
411 of HIV-positive admission and inpatient mortality in Malawi (2012-2019). *Aids.*  
412 2021;35(13):2191-9.
- 413 12. Kanyerere H, Girma B, Mpunga J, Tayler-Smith K, Harries AD, Jahn A, et al. Scale-up  
414 of ART in Malawi has reduced case notification rates in HIV-positive and HIV-negative  
415 tuberculosis. *Public Health Action.* 2016;6(4):247-51.
- 416 13. Chirwa Z, Kayambo F, Oseni L, Plotkin M, Hiner C, Chitsulo C, et al. Extending beyond  
417 Policy: Reaching UNAIDS' Three "90"s in Malawi. *Front Public Health.* 2018;6:69.
- 418 14. Borgdorff MW. New measurable indicator for tuberculosis case detection. *Emerg  
419 Infect Dis.* 2004;10(9):1523-8.
- 420 15. Feasey HRAK, M.; Nzawa Soko, R.; Bottomley, C.; Chiume, L.; Nliwasa, M.; Twabi, H.;  
421 Mpunga, J.A.; Fielding, K.; MacPherson, P.; Corbett, E.L. . OA17-324-09 Impact of active TB  
422 case-finding on case notifications in Blantyre, Malawi: a community-based cluster-  
423 randomised trial (SCALE). *The Union World Conference on Lung Health; Virtual2022*.
- 424 16. National Statistical Office (NSO). *2018 Malawi Population and Housing Census*.  
425 Blantyre City Report. 2021.
- 426 17. United Nations Human Settlements Programme (UN-HABITAT). *Malawi: Blantyre  
427 Urban Profile*. 2011.
- 428 18. World Health Organization. *Tuberculosis Prevalence Surveys: a handbook*. 2011.

- 429 19. Floyd S, Sismanidis C, Yamada N, Daniel R, Lagahid J, Mecatti F, et al. Analysis of  
430 tuberculosis prevalence surveys: new guidance on best-practice methods. *Emerg Themes*  
431 *Epidemiol.* 2013;10(1):10.
- 432 20. Rubin DB. Multiple Imputation after 18+ Years. *Journal of the American Statistical*  
433 *Association.* 1996;91(434):473-89.
- 434 21. van Buuren S. G-OK, Vink G. et al., mice: Multivariate Imputation by Chained  
435 Equations R package 2022 [Available from: [https://cran.r-](https://cran.r-project.org/web/packages/mice/index.html)  
436 [project.org/web/packages/mice/index.html](https://cran.r-project.org/web/packages/mice/index.html)].
- 437 22. Hothorn T. ZA, Farebrother R.W. et al., ltmtest: Testing Linear Regression Models R  
438 Package 2022 [Available from: <https://cran.r-project.org/web/packages/ltmtest/index.html>].
- 439 23. Zeileis A. LT, Graham N., Koell S. . sandwich: Robust Covariance Matrix Estimators R  
440 Package 2022 [Available from: [https://cran.r-](https://cran.r-project.org/web/packages/sandwich/index.html)  
441 [project.org/web/packages/sandwich/index.html](https://cran.r-project.org/web/packages/sandwich/index.html)].
- 442 24. Horton KC, MacPherson P, Houben RMGJ, White RG, Corbett EL. Sex Differences in  
443 Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic  
444 Review and Meta-analysis. *PLoS Medicine.* 2016;13(9).
- 445 25. Frascella B, Richards AS, Sossen B, Emery JC, Odone A, Law I, et al. Subclinical  
446 Tuberculosis Disease—A Review and Analysis of Prevalence Surveys to Inform Definitions,  
447 Burden, Associations, and Screening Methodology. *Clinical Infectious Diseases.*  
448 2021;73(3):e830-e41.
- 449 26. MacPherson P, Webb EL, Kamchedzera W, Joekes E, Mjoli G, Lalloo DG, et al.  
450 Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough  
451 in Malawi (the PROSPECT study): A randomised trial and cost-effectiveness analysis. *PLoS*  
452 *Med.* 2021;18(9):e1003752.
- 453 27. Divala TH, Fielding KL, Kandulu C, Nliwasa M, Sloan DJ, Gupta-Wright A, et al. Utility  
454 of broad-spectrum antibiotics for diagnosing pulmonary tuberculosis in adults: a systematic  
455 review and meta-analysis. *Lancet Infect Dis.* 2020;20(9):1089-98.
- 456 28. Nyirenda T. Epidemiology of Tuberculosis in Malawi. *Malawi Med J.* 2006;18(3):147-  
457 59.
- 458 29. The World Bank. Policy Brief: Optimizing Investments in the Tuberculosis Response  
459 in Blantyre, Lilongwe, and Mzimba Districts, Malawi: Results of a TB Allocative Efficiency  
460 Study. . 2020.
- 461 30. Data reported by countries to WHO and estimates of tuberculosis burden generated  
462 by WHO for the Global Tuberculosis Report [Internet]. 2022 [cited 14/12/2022]. Available  
463 from: <https://www.who.int/teams/global-tuberculosis-programme/data>.
- 464 31. World Health Organisation. Guidelines for intensified tuberculosis case-finding and  
465 isoniazid preventive therapy for people living with HIV in resource-constrained settings.  
466 2011.
- 467 32. PHIA Project. Malawi Population-based HIV Impact Assessment (MPHIA) Summary  
468 Sheet 2020-2021. 2022.
- 469 33. Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. *Clin Microbiol*  
470 *Rev.* 2011;24(2):351-76.
- 471 34. Corbett EL, Charalambous S, Moloji VM, Fielding K, Grant AD, Dye C, et al. Human  
472 immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold  
473 miners. *Am J Respir Crit Care Med.* 2004;170(6):673-9.
- 474 35. Law I, Floyd K. National tuberculosis prevalence surveys in Africa, 2008-2016: an  
475 overview of results and lessons learned. *Trop Med Int Health.* 2020;25(11):1308-27.

- 476 36. Marx FM, Hesselting AC, Martinson N, Theron G, Cohen T. National survey in South  
477 Africa reveals high tuberculosis prevalence among previously treated people. *Lancet Infect*  
478 *Dis.* 2022;22(9):1273.
- 479 37. Chikovore J, Hart G, Kumwenda M, Chipungu GA, Desmond N, Corbett L. Control,  
480 struggle, and emergent masculinities: a qualitative study of men's care-seeking  
481 determinants for chronic cough and tuberculosis symptoms in Blantyre, Malawi. *BMC Public*  
482 *Health.* 2014;14:1053.
- 483 38. Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. *Pulm*  
484 *Med.* 2013;2013:828939.
- 485 39. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2:  
486 screening – systematic screening for tuberculosis disease. 2021.
- 487 40. Habib SS, Asad Zaidi SM, Jamal WZ, Azeemi KS, Khan S, Khowaja S, et al. Gender-  
488 based differences in community-wide screening for pulmonary tuberculosis in Karachi,  
489 Pakistan: an observational study of 311 732 individuals undergoing screening. *Thorax.*  
490 2022;77(3):298-9.
- 491 41. Soko RN, Burke RM, Feasey HRA, Sibande W, Nliwasa M, Henrion MYR, et al. Effects  
492 of Coronavirus Disease Pandemic on Tuberculosis Notifications, Malawi. *Emerg Infect Dis.*  
493 2021;27(7):1831-9.
- 494



**Figure 1: Schematic diagram of number of participants screened for TB & HIV**




Figure 1

## Estimated tuberculosis prevalence by different analytical models

Overall and stratified point prevalence + 95% confidence intervals using robust standard errors




Figure 2